Revenio Group Oyj - Changes board/management/auditors

Revenio Group Corporation: Revenio to renew its Management Team

Revenio Group Oyj, Stock Exchange Release, August 5, 2015 at 12:00


Revenio to renew its Management Team

Revenio  Group Corporation's Board of Directors has  made a decision to grow the
Group's  Management Team as Revenio according  to its strategy focuses to health
technology.

As  of  August  6, 2015 Revenio's  Management  Team is following: CEO Olli-Pekka
Salovaara  (chair), Icare Finland's  CEO Timo Hilden,  Revenio Group's CFO Robin
Pulkkinen  and new  members, Icare  Finland's Sales  and Marketing Director Tomi
Karvo,   Icare   Finland's   R&D  Director  Ari  Kukkonen  and  as  an  external
communications specialist Tiina Olkkonen."I  am pleased that the new Management Team is now completed. The abovementioned
individuals  have been nominated as Management Team members due to their ability
to develop international business and coach Revenio as an energetic team towards
our target. In addition to Icare and eye pressure measurements we are determined
to  launch new innovative  products and methods  for screening and  follow up of
public  health's fundamental diseases.  Our intention is  to further improve the
quality  and lifetime prognosis  of people globally.  Our Management Team has an
important  role  in  our  mission  and  I  wish  the  whole team success in this
important task," states Revenio Group's CEO Olli-Pekka Salovaara.

For further information, please contact:
President & CEO Olli-Pekka Salovaara, tel. +358 40 567 5520
olli-pekka.salovaara@revenio.fi
www.revenio.fi

DISTRIBUTION:
NASDAQ OMX Helsinki
Financial Supervisory Authority (FIN-FSA)
Principal media
www.revenio.fi

The Revenio Group in brief

Revenio is a Finnish health tech group whose core business is in tonometers. The
Revenio Health Tech segment comprises the business operations of Icare Finland
Oy, Revenio Research Oy and Oscare Medical Oy, which specializes in osteoporosis
screening and monitoring. The common denominators of Revenio's business
operations include screening, follow-up and the global need to make cost savings
in health care via preventive measures. Revenio seeks vigorous growth in health
technology, both organically and through acquisitions and mergers. Revenio aims
at developing even more efficient and easily adopted methods for the early-stage
detection of diseases with significance for public health. The focus of
Revenio's screening technology lies on the early detection of glaucoma,
osteoporosis, skin cancer and asthma, and the monitoring of these during the
treatment process.

In 2014, the Revenio Group's net sales totaled MEUR 16.0, with its operating
profit (EBIT) from continuing operations standing at 27.5%. The Revenio Group
Corporation is listed on NASDAQ OMX Helsinki.


[HUG#1943720]